Concepts (115)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fragile X Mental Retardation Protein | 15 | 2018 | 65 | 3.720 |
Why?
|
| Fragile X Syndrome | 15 | 2024 | 113 | 3.210 |
Why?
|
| Tremor | 12 | 2024 | 41 | 3.210 |
Why?
|
| Ataxia | 11 | 2024 | 38 | 2.820 |
Why?
|
| Heterozygote | 9 | 2016 | 48 | 1.690 |
Why?
|
| Trinucleotide Repeat Expansion | 7 | 2016 | 24 | 1.450 |
Why?
|
| Parkinson Disease | 3 | 2025 | 65 | 1.210 |
Why?
|
| Postural Balance | 3 | 2025 | 11 | 0.900 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 8 | 0.890 |
Why?
|
| Health Status Disparities | 1 | 2025 | 7 | 0.890 |
Why?
|
| Humans | 22 | 2025 | 2957 | 0.860 |
Why?
|
| Parkinsonian Disorders | 3 | 2016 | 24 | 0.750 |
Why?
|
| Middle Aged | 14 | 2025 | 792 | 0.740 |
Why?
|
| Male | 18 | 2025 | 1860 | 0.720 |
Why?
|
| Female | 15 | 2025 | 1724 | 0.710 |
Why?
|
| Aged | 13 | 2025 | 956 | 0.700 |
Why?
|
| Movement Disorders | 2 | 2016 | 6 | 0.560 |
Why?
|
| Memory Disorders | 2 | 2016 | 33 | 0.540 |
Why?
|
| Trinucleotide Repeats | 1 | 2018 | 8 | 0.540 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 19 | 0.500 |
Why?
|
| DNA Methylation | 1 | 2016 | 44 | 0.490 |
Why?
|
| Phenotype | 4 | 2025 | 75 | 0.480 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 92 | 0.450 |
Why?
|
| Adult | 7 | 2025 | 794 | 0.390 |
Why?
|
| Cognitive Dysfunction | 1 | 2014 | 165 | 0.360 |
Why?
|
| Alzheimer Disease | 1 | 2014 | 250 | 0.350 |
Why?
|
| Executive Function | 1 | 2011 | 15 | 0.340 |
Why?
|
| Aged, 80 and over | 6 | 2016 | 567 | 0.280 |
Why?
|
| Genetic Testing | 4 | 2014 | 17 | 0.260 |
Why?
|
| Cerebellar Ataxia | 1 | 2006 | 2 | 0.250 |
Why?
|
| Central Nervous System Agents | 1 | 2006 | 4 | 0.250 |
Why?
|
| Cohort Studies | 3 | 2016 | 233 | 0.240 |
Why?
|
| Parietal Lobe | 1 | 2025 | 6 | 0.230 |
Why?
|
| Huntington Disease | 1 | 2025 | 12 | 0.230 |
Why?
|
| Cerebral Cortex | 1 | 2025 | 28 | 0.230 |
Why?
|
| Psychomotor Performance | 1 | 2025 | 34 | 0.230 |
Why?
|
| Gait Ataxia | 1 | 2005 | 2 | 0.230 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 5 | 0.230 |
Why?
|
| Prefrontal Cortex | 1 | 2025 | 34 | 0.230 |
Why?
|
| Observational Studies as Topic | 1 | 2025 | 6 | 0.220 |
Why?
|
| Quality of Life | 1 | 2025 | 39 | 0.220 |
Why?
|
| Prospective Studies | 1 | 2025 | 203 | 0.210 |
Why?
|
| Alleles | 2 | 2016 | 65 | 0.210 |
Why?
|
| United States | 1 | 2025 | 243 | 0.210 |
Why?
|
| Age of Onset | 3 | 2016 | 22 | 0.200 |
Why?
|
| RNA, Messenger | 2 | 2018 | 59 | 0.190 |
Why?
|
| Biomechanical Phenomena | 3 | 2016 | 95 | 0.170 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 97 | 0.140 |
Why?
|
| Genotype | 2 | 2016 | 85 | 0.140 |
Why?
|
| Gait | 2 | 2016 | 36 | 0.130 |
Why?
|
| Mosaicism | 1 | 2016 | 5 | 0.130 |
Why?
|
| Siblings | 1 | 2016 | 6 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 16 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2016 | 9 | 0.120 |
Why?
|
| Mutation | 2 | 2007 | 77 | 0.120 |
Why?
|
| Computers | 1 | 2015 | 4 | 0.120 |
Why?
|
| Sex Factors | 3 | 2011 | 72 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2015 | 10 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 7 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2015 | 27 | 0.120 |
Why?
|
| Reaction Time | 1 | 2015 | 29 | 0.120 |
Why?
|
| Activities of Daily Living | 1 | 2015 | 28 | 0.120 |
Why?
|
| Hyperkinesis | 1 | 2013 | 8 | 0.100 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 7 | 0.100 |
Why?
|
| Animals | 1 | 2016 | 1050 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2011 | 167 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2011 | 32 | 0.080 |
Why?
|
| Neurologic Examination | 2 | 2006 | 9 | 0.070 |
Why?
|
| Family Health | 2 | 2007 | 8 | 0.070 |
Why?
|
| Heredodegenerative Disorders, Nervous System | 1 | 2008 | 2 | 0.070 |
Why?
|
| Genetic Carrier Screening | 1 | 2007 | 9 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 7 | 0.070 |
Why?
|
| Point Mutation | 1 | 2007 | 12 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2007 | 4 | 0.060 |
Why?
|
| Carbidopa | 1 | 2006 | 2 | 0.060 |
Why?
|
| Dopamine Agonists | 1 | 2006 | 7 | 0.060 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2006 | 3 | 0.060 |
Why?
|
| Levodopa | 1 | 2006 | 4 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2006 | 7 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2006 | 8 | 0.060 |
Why?
|
| Anxiety Disorders | 1 | 2006 | 16 | 0.060 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2025 | 3 | 0.060 |
Why?
|
| Treatment Outcome | 1 | 2006 | 186 | 0.060 |
Why?
|
| Cerebellum | 1 | 2005 | 8 | 0.060 |
Why?
|
| Atrophy | 1 | 2005 | 10 | 0.060 |
Why?
|
| Health Surveys | 1 | 2005 | 9 | 0.060 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 19 | 0.060 |
Why?
|
| Syndrome | 1 | 2005 | 21 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 33 | 0.060 |
Why?
|
| Age Factors | 1 | 2005 | 89 | 0.060 |
Why?
|
| Stroke | 1 | 2005 | 49 | 0.050 |
Why?
|
| Prodromal Symptoms | 1 | 2024 | 5 | 0.050 |
Why?
|
| DNA Repeat Expansion | 1 | 2004 | 5 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2004 | 9 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 39 | 0.050 |
Why?
|
| Biomarkers | 1 | 2024 | 101 | 0.050 |
Why?
|
| Posture | 1 | 2016 | 8 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2016 | 23 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2013 | 12 | 0.030 |
Why?
|
| Movement | 1 | 2013 | 16 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2013 | 142 | 0.020 |
Why?
|
| Young Adult | 1 | 2013 | 187 | 0.020 |
Why?
|
| Child | 1 | 2013 | 197 | 0.020 |
Why?
|
| Adolescent | 1 | 2013 | 247 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 50 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 77 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2007 | 4 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 9 | 0.020 |
Why?
|
| Mass Screening | 1 | 2007 | 12 | 0.020 |
Why?
|
| Disease Progression | 1 | 2007 | 99 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 147 | 0.020 |
Why?
|
| Time Factors | 1 | 2007 | 208 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2005 | 238 | 0.010 |
Why?
|
| Pedigree | 1 | 2004 | 5 | 0.010 |
Why?
|
| California | 1 | 2004 | 13 | 0.010 |
Why?
|